Objective: Chronic infusion with angiotensin II increases blood pressure and activates growth mechanisms to produce hypertrophy of the heart and vessels. In order to better understand mechanisms of angiotensin II induced vascular hypertrophy, this study aimed to determine whether heparin, a potent inhibitor of smooth muscle proliferation mechanisms, was able to inhibit vascular hypertrophy. Ž . Methods: Angiotensin II 100, 200 or 300 ngrminrkg s.c. or a saline vehicle control were infused into rats for 14 days. A separate Ž . Ž . group of animals were co-infused with heparin 0.3 mgrhrkg i.v. and angiotensin II 200 ngrminrkg s.c. to test whether hypertension or hypertrophy were antagonized. Blood pressure was measured by tail cuff method and vessel media cross sectional area was measured by morphometry in aorta and mesenteric arteries. Results: Blood pressure elevation and cardiovascular hypertrophy produced by angiotensin II were strongly dose-dependent. Hypertrophy responses at 14 days of treatment also appeared to be influenced partly by local factors as medial cross sectional area was increased more in mesenteric arteries than in thoracic aorta, and left ventricle weight was least affected. Heparin treatment did not influence the increase of blood pressure in angiotensin II infused animals, but the mesenteric vascular hypertrophy response due to angiotensin II was inhibited by approximately 50%. Inhibition of a modest cardiac hypertrophy and aortic medial hypertrophy did not reach significance. Conclusions: Angiotensin II infusion produced vascular medial hypertrophy and increased blood pressure, however the inhibitory effect of heparin on hypertrophy in mesenteric arteries was not mediated through angiotensin II induced vasoconstriction or blood pressure elevation. These data suggest that heparin interferes directly with the hypertrophy mechanism in mesenteric arteries, and that heparin-sensitive growth mechanisms are important in mediating angiotensin induced mesenteric vascular hypertrophy. q 1998 Elsevier Science B.V.
Introduction
Chronic infusion of the vasoconstrictor angiotensin II w x produces hypertension 1 and is associated with cardiac w x and vascular hypertrophy 2,3 . Angiotensin II also promotes growth of vascular smooth muscle cells in culture, suggesting that specific cellular growth mechanisms, independent from blood pressure elevating effects, are involved in mediating the hypertrophy responses. A fundamental role for angiotensin II in regulating vascular smooth muscle growth is indicated by the finding that DNA synthesis ) Ž .
Ž . Corresponding author. Tel.: q61 3 95224341; Fax: q61 3 95211362; E-mail: rod.dilley@baker.edu.au in injured rat carotid arteries is also increased by anw x giotensin II infusion 3 and inhibited by angiotensin con-Ž . w x verting enzyme ACE inhibitors 4 and angiotensin II w x receptor antagonists 5 . The mechanisms by which angiotensin II promotes growth have not been fully eluciw x dated, but increases in protein 6-8 and DNA synthesis w x 9,10 in angiotensin II stimulated cultures are associated w x with increased expression of cellular growth factors 10,11 w x and growth factor receptors 10 , while growth can be inhibited by interfering with autocrine growth mechanisms w x 12 . Similar mechanisms may be activated in vivo where ( ) infusion of angiotensin II also reportedly increases aortic w x growth factor and receptor mRNA expression 13, 14 and w x DNA synthesis 3,15 . In mesenteric vessels of angiotensin II infused rats there is activation of DNA synthesis and w x increased expression of extracellular matrix genes 16 .
Much of our knowledge on angiotensin II induced growth mechanisms has come from aortic smooth muscle cells in culture, however the consequences of angiotensin II induced growth are of greatest significance to hyperw x tension in the resistance vasculature in vivo. Folkow 17 has suggested that hypertrophy of these vessels creates an amplifier of constrictor mechanisms, producing greater increases in resistance and thus promoting the development of hypertension. The importance of angiotensin II in creating these amplifiers is indicated in studies with anw x giotensin converting enzyme inhibitors 18,19 and anw x giotensin II receptor antagonists 20,21 in primary hypertension. Development of abnormal vascular amplifiers w x w x 18,20 and hypertrophy 19,21 in spontaneously hypertensive rats is prevented and hypertension is ameliorated when animals are treated with these angiotensin II lowering or receptor antagonising drugs. However, the effect of angiotensin II in these experiments is confounded by the effect of blood pressure lowering and so growth mechanisms which are regulated by wall tension may also be significant contributors to smooth muscle growth control in these circumstances.
The role of angiotensin II in hypertrophy may be more directly tested by examining the influence of growth inhibitors during development of hypertension, without involving blood pressure directly. The anticoagulant heparin w x is a potent smooth muscle growth inhibitor 22 and heparin-like glycosaminoglycans secreted from endothelium w x w x 23 and smooth muscle cells 24 are thought to play a w x role in regulating cell replication in the vessel wall 22,25 . Vascular growth may result from an alteration in the normal balance of inhibitory and stimulatory influences in the vessel wall. For example, removal of the endothelium with a balloon catheter leads to exposure of smooth muscle cells to mitogenic influences from adhering platelets and other cells in the vessel wall, but regrowth of the endothew x lium appears to restore growth inhibition 22,25 . Heparin infusion into injured vessels mimics this growth inhibition w x capacity in some vascular repair models 22 . It is not known whether the interaction between growth stimulation and growth inhibition is important in angiotensin II induced vascular hypertrophy. Vascular injury studies have shown that growth inhibitory effects of heparin and ACE w x inhibitors 26 are additive, suggesting that angiotensin II and heparin may affect growth through different mechanisms. However, heparin may inhibit proliferation of vascular smooth muscle cells by altering the activity of growth w x w x factors 27,28 or growth inhibitors 29 which are regulated by angiotensin II in cultured cells. The aim of the present study therefore was to examine whether heparin infusion is able to inhibit the development of vascular hypertrophy in angiotensin II induced cardiovascular growth. Council of Australia guidelines. After three days recovery, systolic blood pressure was measured in conscious rats on Ž an automated multi-channel system IITC Life Science . Instruments, Woodland Hills, CA with tail cuffs to constrict caudal artery flow and photoelectric sensors to detect the tail pulses as cuff pressure was reduced. Animals were maintained at approximately 278C for 10-20 min to encourage caudal artery vasodilatation.
Methods

Animal models
Tissue collection
At 2 weeks after pump placement the rats were anaes-Ž . thetized Pentobarbitone, 60 mgrkg, i.p. and the abdominal aorta was cannulated for perfusion of the mesenteric circulation with fixative. Immediately prior to perfusion Ž the heart and descending thoracic aorta between left sub-. clavian artery and diaphragm were removed. The atria were discarded and the remainder of the heart was separated into right ventricle and left ventricle plus septum before weighing. The thoracic aorta was cleared of adherent fat and intercostal arteries, weighed and then a ring 2-3 mm long was taken from the distal end of the aorta Ž and placed into fixative 2.5% glutaraldehyde in 0.1 molrl . phosphate buffer, pH s 7.4 for later morphometric analysis.
Morphometry
The mesenteric circulation was perfused with Hank's Ž . balanced salt solution containing papaverine 0.1 mgrml 
Ž
. and heparin 2.5 unitsrml for 5 min at 1 mlrminr100 g body weight, then with 2.5% glutaraldehyde in 0.1 molrl Ž . phosphate buffer pH s 7.4 for 10 min at the same flow rate. The mesenteric bed was removed and immersed in fixative overnight. Four vessel segments were taken from the third branch order vessels proximal to the intestinal Ž . margin approximate inner diameter of 250 mm for em-Ž bedding in epoxy resin Polarbed, Polaron, Watford, Herts, . England . Cross sections from the thoracic aorta and four mesenteric vessels were cut and stained with toluidine blue in 1% Borax. Images of thoracic aorta and mesenteric artery cross sections were projected onto a digitising tablet and areas bounded by inner and outer elastic laminae were measured using a custom made morphometry software package. Medial area was calculated as the difference between the two values. In all vessels studied the intima consisted of only a single layer of endothelium, which contributed very little to the vessel cross sectional area measurement, and so the lumen area was calculated as that bounded by the inner elastic lamina.
Statistics
Group comparisons were made by one way analysis of variance for the angiotensin dose experiment and two way Ž . Fig. 2 . Morphometric analysis of vascular hypertrophy. A media cross-Ž . sectional area in thoracic aorta, B media cross-sectional area in mesen-Ž . teric arteries and C mediarlumen area ratio in mesenteric arteries after 2 weeks of angiotensin II infusion hypertension. ) P -0.05 compared to Ž . vehicle treated 0 ngrminrkg angiotensin II control group.
analysis of variance for the heparin inhibition experiment. Individual treatment effects were analyzed by orthogonal w x partitioning of the sums of squares 30 into angiotensin II dose effects, and for the heparin inhibition experiment into effects of angiotensin II, heparin and an interaction term Ž . Sigmastat, Jandel Scientific, San Rafael CA, USA . Comparisons between individual groups were made by Bonfer- roni's t test. Data are presented as mean " SEM. A P value less than 0.05 was considered significant.
Results
Effects of angiotensin II treatment
Blood pressure, cardiac hypertrophy and body weight
Systolic blood pressure increased rapidly within the first Ž . three days of angiotensin II infusion Fig. 1 , and by 6 days all three treatment groups were significantly higher Ž . than the control group P -0.01 . The blood pressure reached was highly dose-dependent with analysis of variance for treatment dose effects being significant at P -0.01 at both 6 days and 14 days. The mean value for LD rats after 14 days angiotensin II infusion was 32 mm Hg greater than control, MD was 51 mm Hg greater than control and HD was 76 mm Hg greater than control. Ž Left ventricle weight increased significantly P -0.05, . ANOVA with increasing rate of angiotensin II infusion Ž . Table 1 , however these effects were only small in magni-Ž . tude 4-11% and did not reach significance when Bonfer-Ž . roni's t test was used Table 1 . There was also a significant dose related increase in the left ventriclerbody weight ratio, however in HD rats body weights were significantly Ž . lower Table 1 , such that an 11% increase in left ventricle weight and a 21% decrease in body weight produced a 40% increase in left ventriclerbody weight ratio Ž . LVrBW . The body weight was not affected in MD and Ž LD groups and the increase in LVrBW 5% and 12% . respectively was due to the increase in left ventricle Ž . weight 4% and 9% .
Vascular hypertrophy
Thoracic aorta weightrlength also increased significantly with increasing dose of angiotensin II; being 10%, Ž . 18% and 23% in LD, MD and HD respectively Table 1 . These percentage increases were twice as large as the LV weight increases. Angiotensin II significantly increased the mass of smooth muscle tissue in the aorta, as cross sectional area of the media in thoracic aorta was significantly larger than controls in all three angiotensin treatment Ž . Ž groups Fig. 2A and these increases 23% LD, 25% MD, . 53% HD were approximately four-fold more than the LV weight increases. This suggests that angiotensin II infusion was a more potent activator of hypertrophy mechanisms in aortic smooth muscle than in the heart of the same animals.
The mesenteric vasculature showed the greatest hyper-Ž . trophy responses to angiotensin II infusion Fig. 2B ; again these changes were significantly dose-dependent with the medial cross sectional area in LD rats 32% larger than controls, in MD 54% larger and in HD rats 88% larger. There was also a significant increase in mediarlumen area Ž ratio in the mesenteric vessels LD 44%, MD 37%, HD . 59% , but no significant effect on lumen cross sectional Ž . mm ; P ) 0.05 . As in aorta, the effect of angiotensin II infusion on medial cross sectional area and mediarlumen ratio was greater than its effect on LV weight or LVrBW ratio.
Effects of heparin treatment
Analysis of variance was used in this study to test for significance of an angiotensin II effect and the influence of . Ž . mgrhrkg infusion on vascular morphometry measurements A media Ž . cross-sectional area in thoracic aorta, B media cross-sectional area in Ž . mesenteric arteries and C mediarlumen area ratio in mesenteric arteries after 2 weeks of treatment. ) P -0.05 compared to vehicle treated control group. † P -0.05 compared to angiotensin II treated group. heparin on responses to angiotensin II infusion. Angiotensin II infused for 14 days increased blood pressure Ž . Ž . Fig. 3 and slightly lowered body weight Table 2 , but Ž . did not affect hematocrit Table 2 . Heparin had no significant effect on blood pressure, body weight or hematocrit, either in the presence or absence of angiotensin II.
Consistent with the blood pressure data, heparin treatment had no significant effect on left ventricle Ž . weightrbody weight ratio Table 2 , while the angiotensin II effect was significant, increasing LVrBW by 23% when infused alone, and by 12% in the presence of heparin. This 50% reduction in cardiac hypertrophy response was largely due to a small protective effect of heparin infusion on the body weight-reducing effects of angiotensin II infusion; there were no significant effects on left ventricle weight. Aorta weight also increased significantly with angiotensin Ž . II 31% , while heparin had no significant effect, as a 23% difference remained between heparin treated and Ž . heparinrang II treated groups Table 2 . Angiotensin II Ž . infusion induced a 30% hypertrophy saline vs. ang II of the medial layer of the aorta and although heparin infusion reduced the difference in means by approximately 50% Ž . 30% vs. 16% , the analysis of variance showed no signifi-Ž . cant interaction term P s 0.19 and the effect of heparin Ž . did not reach significance P s 0.071 . There was no significant effect of heparin treatment in the non-hyper-Ž . trophied vessels of saline infused rats Fig. 4A . Ž . In mesenteric vessels Fig. 5 , heparin inhibited the medial cross sectional area increase due to the angiotensin Ž . II infusion by approximately 50% 65% vs. 34%, Fig. 4B , whereas there was no effect of heparin in saline treated animals. This was reflected in the ANOVA as significant Ž . effects due to angiotensin II and heparin Table 3 , but also Ž . with a significant interaction term P -0.05 , indicating that heparin had specific effects on the angiotensin II induced hypertrophy responses but none on heparin-treated controls. Despite these significant reductions in medial hypertrophy responses by heparin in angiotensin II treated animals, mesenteric artery medial area remained signifi-Ž . cantly greater than in heparin treated controls Fig. 4B . In the ANOVA of lumen cross sectional area measurements, angiotensin treatment tended to increase lumen size and Ž .
Ž . Ž . Fig. 5 . Photomicrographs of mesenteric vessel cross sections from A saline, B angiotensin II and C heparin plus angiotensin II treated animals. Ž . toluidine blue stain, bar s100 mm . . 1.7 = 10 mm ; P ) 0.05 . The mediarlumen ratio increase due to angiotensin II was also significant, and the increase in means was 60% lower in the presence of Ž . heparin 37% vs. 14%, Fig. 4C , however these data were more variable than the media cross sectional areas and neither the heparin effect nor the interaction term reached Ž . significance Table 3 .
Discussion
The major finding of this study was that infusion of heparin specifically inhibited the mesenteric vascular hypertrophy induced by angiotensin II infusion. The inhibition was apparently selective for the vascular hypertrophy mechanism stimulated by angiotensin II, as heparin did not reduce the extent of blood pressure elevation or the body weight, and cardiovascular mass in normotensive animals infused with heparin was also unaffected. In contrast to reports on heparin administered subcutaneously to spontaw x neously hypertensive rats 31 , we found no significant effect on hematocrit levels in these animals. Taken together these findings suggest that the inhibition was directed through the specific growth mechanisms initiated by angiotensin II infusion, rather than through a secondary effect on blood pressure, hematocrit or body growth.
Infusion of angiotensin II was a potent hypertensive stimulus and produced significant vascular hypertrophy at all three doses examined. The rate of blood pressure increase, the level reached at the end of the second week of infusion and the amount of cardiac and vascular hypertrophy were largely dependent upon the dose of angiotensin II administered. With this experimental design it is not possible to separate the effects of increased angiotensin II exposure and increased blood pressure on vascular growth responses. It is apparent, however, that the vascular responses were quantitatively different from those in the heart, with a proportionately larger increase in the Ž . Ž . mesenteric artery 32%-88% and aorta media 23%-53% Ž . than in the left ventricle 4-11% . These data imply that vascular mass rises more or faster than cardiac mass in this model, despite presumably similar exposure to increases in blood pressure and angiotensin II. Studies with angiotensin receptor antagonists show that angiotensin II receptor occupancy is important in some cardiac hypertrophy mechaw x nisms 20,32 , however the extent of cardiac hypertrophy in this and other studies using an angiotensin II infusion w x model 2,16 would suggest that increases in both circulating angiotensin II and wall stress due to blood pressure elevation produce only a relatively small cardiac hypertrophy at this time. In contrast, the mesenteric vasculature and the aorta had a large and strongly dose-dependent hypertrophy. The extent of hypertrophy, in the presence of even relatively modest pressure elevations in LD treatment, supports a more direct influence of angiotensin II infusion on medial smooth muscle cells. It is not unreasonable to expect a direct action of angiotensin II to produce medial hypertrophy in vivo, given its effects on smooth w x w x muscle cellular 6 and extracellular protein 8 production, w x w x leading to cellular hypertrophy 7 or hyperplasia 9 in vitro. These effects might be mediated by a direct influence on cellular growth mechanisms, as exposure to angiotensin II leads to increased expression of protow x oncogenes myc and fos 33 as well as increased PDGF w x w x 10,12,34 and PDGF receptor expression 10 . TGF-b w x expression is also increased 9,12 and interference with bFGF and TGF-b1 mRNA production with anti-sense oligonucleotides decreases or increases the growth rew x sponses respectively 12 . Angiotensin II in vivo might stimulate similar mechanisms, as acute angiotensin II infusion also produces a small but rapid increase in PDGF B w x chain mRNA in the vascular wall 13 and chronic infusion of angiotensin II increases EGF receptor expression and ligand binding along with increasing the rate of smooth w x muscle cell DNA synthesis 3,14 . Further study is necessary to determine whether some or all of these mechanisms are activated in resistance vessels.
In the present study, heparin was found to inhibit the mesenteric vascular growth mechanisms activated by angiotensin II infusion by an average of approximately 50%. Thus, the magnitude by which heparin inhibited mesenteric vascular hypertrophy was similar to that which it inhibits proliferative neointima formation after removal of endothew x w x lium 22 . Wiener et al. 16 have shown that angiotensin II infusion produces significant medial PCNA expression, indicating DNA synthesis in mesenteric vessels and Black w x et al. 35 have found that mesenteric vessel medial hypertrophy due to angiotensin II infusion occurred predominantly by hyperplasia in spontaneously hypertensive rats. Together with the present study, these findings suggest that heparin is able to inhibit smooth muscle cell proliferative responses in the absence of endothelium after injury and in the presence of intact endothelium in these mesenteric arteries of hypertensive rats.
( )The mechanism of heparin action in reducing smooth muscle hyperplasia both in vivo and in vitro remains unknown, despite considerable interest in the last decade and a half. Heparin may act by depleting the local activity of secreted heparin-binding growth factors, for example heparin binds PDGF A chain and inhibits its mitogenic w x activity 27 . Heparin also inhibits bFGF stimulated growth w x responses of endothelial and smooth muscle cells 28, 36 and is able to deplete the amount of bFGF present in the w x wall of injured vessels 28 . Alternatively, heparin may increase activity of a growth inhibitor, as it increases the w x activity of TGFb 29 in cultured cells, which is capable of inhibiting smooth muscle proliferation and encourages celw x lular hypertrophy 29,37 . Clowes et al. have shown that heparin also directly inhibits smooth muscle cell matrix degradation and inhibits replication following vascular inw x jury 38,39 . Part of heparin's growth inhibitory effects might be mediated by inhibition of intracellular kinases w x involved in signal transduction 40 and regulation of w x transcription activator proteins 41 . These data come from experiments in vitro or injury studies in vivo, and so the contribution of each of these mechanisms to vascular growth inhibition in hypertension is unknown, yet our data are supportive of a role for alterations in this angiotensin II infusion model of the balance between growth stimulation and inhibition involving heparin-like compounds secreted by endothelium and smooth muscle. Recent evidence has shown that the extracellular matrix is altered in mesenteric w x vessels of angiotensin II infused rats 16 as part of the hypertrophy mechanism in this model. More specific studies on alteration of growth regulatory matrix components in these vessels may be worthwhile to determine if increases in growth stimulators andror growth inhibitors are involved in the hypertrophy process.
Heparin treatment inhibited the vascular hypertrophy produced by angiotensin II infusion but the hypertensive effects of angiotensin II infusion remained. Similar separation of vascular hypertrophy and blood pressure elevation in angiotensin II infusion models occurs in hydralazine treated rats, where blood pressure elevation is prevented w x without affecting vascular hypertrophy 2 , and in prazosin treated rats, where DNA synthesis is reduced without w x affecting blood pressure 17 . These studies do not appear to support the hypothesis that a slow pressor effect of w x angiotensin II 42 is solely due to hypertrophy of the resistance vasculature and development of vascular amplifiers. However continued elevation of blood pressure may be due to secondary effects of angiotensin II infusion, such w x as those documented in the kidney 43 , or as suggested by the effects of prazosin, the enhancement of sympathetic w x activity by angiotensin II 15 . It is not yet known whether these also are affected by heparin. Interestingly, heparin treatment is reported to have antihypertensive effects in w x stroke prone spontaneously hypertensive rats 44 , sponta-Ž . neously hypertensive rats SHR and one-kidney one clip w x Goldblatt hypertension in rats 31 . This has been partly w x attributed to lowering of hematocrit 31,44 , although we did not find this in our study, perhaps due to differences in the dose of heparin administered, or to the continuous administration of heparin by osmotic mini-pump rather than by the acute high doses produced by injection. These effects are not due to the anticoagulant properties of heparin as non-anticoagulant fractions of heparin are w x equally effective in lowering blood pressure 45 . Heparin w x is not a direct vasodilator 46 and has no effect on blood w x pressure responses to acute angiotensin II infusion 46 . However, heparin treatment raises plasma renin levels and paradoxically inhibits angiotensin converting enzyme acw x tivity 31,47 , resulting in lowered plasma angiotensin II levels. Absence of an effect of heparin on blood pressure in the present study would suggest that the circulating renin angiotensin system was not significantly altered in this model. In the angiotensin II infusion group, blood pressure was likely maintained by the elevated angiotensin II levels produced by constant infusion. We cannot exclude an effect of heparin on local tissue formation of angiotensin II. Taken together this data is consistent with heparin having a separate and direct effect on vascular wall hypertrophy mechanisms in hypertension, independent from any effects on blood pressure.
In conclusion it has been shown that angiotensin II infusion has increased blood pressure and induced widespread cardiovascular hypertrophy by a dose-dependent mechanism. The anti-trophic effect of heparin was not dependent on blood pressure lowering, implicating a more direct mechanism of hypertrophy in this model, possibly involving either increased growth stimulation or decreased growth inhibition. The finding that heparin can effectively inhibit hypertrophy might provide a promising avenue for clinical intervention in the vascular changes due to acute hypertension and more specifically to the growth processes mediated via angiotensin II formation. Low molecular weight heparin fractions, with lowered anticoagulant activity but equivalent effect on experimental smooth muscle w x cell growth 48 may be worth further exploration in this regard. The mechanism of vascular hypertrophy induced by angiotensin II infusion is not known, but our data show that it includes heparin-sensitive elements, suggesting that vascular wall mass may in part be regulated by the heparin-like molecules normally present in the vessel wall. 
